spacer
home > ebr > summer 2003 > preclinical juvenile toxicity studies: will it be safe for children?
PUBLICATIONS
European Biopharmaceutical Review

Preclinical Juvenile Toxicity Studies: Will it be Safe for Children?

The last issue of EPC highlighted the growth in paediatric clinical trials and difficulties in performing studies in children. Similar gaps in study cover have become an issue in preclinical studies and it is only in recent years that any studies have focused on the potential effects of direct treatment of young animals and on possible long-term effects.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Audrey Bottomley, David Myers and Chris Willoughby of the Reproductive Studies Group at Huntingdon Life Sciences

Audrey Bottomley is a UK Registered Toxicologist and the Principal Consultant Toxicologist to the Reproductive Studies Group with over 30 years' experience in reproductive and developmental toxicology. She is now primarily concerned with advising external clients and Huntingdon Life Sciences staff on the design and interpretation of reproductive studies.


David Myers is a Senior Study Director and Consultant Toxicologist within the Reproductive Studies Group. He has a PhD in age-related changes in the behaviour and brain of the ageing female mouse and is a specialist in the effects of treatments on behaviour in rodents. David is directly involved with study design management and interpretation in the developing field of behavioural testing.


Chris Willoughby is Head of the Reproductive Studies Group at Huntingdon Life Sciences and has qualifications in pharmacy and toxicology. He has worked in reproductive toxicology with Huntingdon Life Sciences since 1974 and has extensive experience managing studies of all types.

spacer
Chris Willoughby
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Sartorius Stedim Biotech Launches New Services for Mammalian Cell Bank Manufacturing

GOETTINGEN, Germany and GLASGOW, UK, August 08, 2019 / B3C newswire / -- Sartorius Stedim Biotech (SSB), a leading partner of the biopharmaceutical industry, today announced the launch of new services for mammalian cell bank manufacture under GMP conditions. These services are offered by its subsidiary, Sartorius Stedim BioOutsource, an experienced contract testing organization (CTO) based in Glasgow, UK, and in Cambridge, Massachusetts, USA.
More info >>

White Papers

A Rules Based Approach to Labelling and Artwork Management

Kallik

Many organisations today are experiencing unprecedented demands from regulatory authorities and consumers alike for product labelling to be made clearer and more informative. Forthcoming regulations (including the new EU MDR regulations coming into force May 2020) also require that labelling content to be published electronically in addition to print. As companies seek to continuously differentiate themselves in established markets as well as gain entry into new territories, the increase in both volume and complexity of product and market variations will have a direct impact on labelling.
More info >>

 
Industry Events

World Vaccine Congress Europe

28-31 October 2019, Barcelona, Spain

The 20th annual World Vaccine Congress Europe is taking place 28-31 Oct in Barcelona. It’s the biggest and most established European vaccine event with over 250 speakers, 700+ senior vaccine attendees, hundreds of networking hours. It cover key topics across the complete vaccine value chain bringing together: • Government • big pharma • big biotech • SME Biotech • academia and the wider service provider community and their partners to discuss scientific, clinical and strategic advances and opportunities. The event has already confirmed over 200 speakers from Human Vaccine Project, OECD, CEPI, European Commission, FDA, WHO, OECD, NIH, GSK and many more… There is a Super Early Bird offer available – Find Out More www.terrapinn.com/WVCEU/EBR
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement